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Background: Thymic epithelial tumors (TET) are rare neoplasms with inconsistent treatment strategies. 
When researching for molecular pathways to find new therapies, the correlation between specific molecular 
markers and outcome has only rarely been investigated. The aim of this study was to investigate the 
correlation between survival, metastatic potential and invasiveness of aggressive subtypes of TET and 
immunohistochemical markers.
Methods: Overall survival (OS), disease-free survival (DFS), progression-free survival (PFS) and metastasis-
free survival (MFS) of patients with WHO type B2/B3 mixed type thymoma (MT), thymoma type B3 (B3) 
and thymic carcinoma (TC), undergoing surgery [1998–2013] were determined. Tumor specimens were 
stained using a tissue microarray (TMA) (CD117, CD5, p63, p40, p21, p27, p53, Bcl-2, Ki67, podoplanin, 
synaptophysin, PTEN and Pax8). Invasive behavior of primary tumors and the presence of extrathoracic 
metastases were assessed.
Results: We found in 23 patients included into this study (four MT, ten B3, nine TC) that (I) p21 
expression in the cytoplasm significantly correlated with a decrease of OS (P=0.016), PFS (P=0.034) and 
MFS (P=0.005); (II) MFS was significantly shorter when the combination of p21-low p27-low p53-high was 
present (P=0.029); and (III) nuclear p27 (P=0.042), Ki-67 (P=0.024) and podoplanin (P=0.05) expression 
correlated with the presence of extrathoracic metastases. 
Conclusions: The main finding of this study is that cytoplasmic p21 expression negatively influences 
the outcome of malignant TETs and correlates with metastatic activity. Additionally, selected 
immunohistochemical markers correlate with the distant metastatic potential of TETs. These results may 
contribute to the stratification of diagnosis and improvement of treatment strategies for thymic malignancies.
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Introduction
Thymic epithelial tumors (TET) are rare neoplasms 
arising from epithelial cells of the thymus whose cause of 
development remains unknown until today (1). Due to the 
rarity of TETs, treatment strategy is not yet standardized 
and mostly based on retrospective reviews (1-3). The 
pathological classification of TETs has been the subject 
of discussion over many years. The revised World Health 
Organization (WHO) classification and the staging system 
according to Masaoka with modifications by Koga et al. are 
the ones commonly employed and have been shown to be of 
prognostic relevance (4). The WHO classification stratifies 
TETs into six entities according to the morphology of the 
tumor cells and the quantity of non-tumoral lymphocytes: 
A, AB, B1, B2, B3 and thymic carcinoma (TC). TCs are 
further classified into several subtypes including squamous 
cell carcinoma, basaloid carcinoma, mucoepidermoid 
carcinoma and neuroendocrine carcinoma. TCs account for 
15–20% of TETs, and are aggressive tumors with frequent 
invasion into adjacent organs and metastatic spread, mostly 
into lung, bone and liver (5). All thymoma subtypes can 
present in advanced stages and exhibit malignant behavior, 
although some of them more frequently (6,7). The 
Masaoka-Koga staging system indicates the invasiveness of 
the tumor, TETs with stage I being completely encapsulated 
and with stage IVB showing lymphatic or hematogenous 
metastasis (8). The prognosis of TETs is variable with a 
5- and 10-year overall survival (OS) of 95% and 91% for 
thymoma and 60% and 40% for TC, respectively (9,10).
In the past few years, the molecular pathways involved in 
the development of TETs have been extendedly researched. 
The growing knowledge about tumor biology has led to 
clinical trials testing molecularly targeted therapies, most of 
them with disappointing results (1,11). Tumorigenesis is a 
result of genetic changes and abnormal protein expression 
in the cell. These molecular alterations may be visible 
with genomic analysis or immunohistochemical staining. 
Several studies have investigated the diagnostic relevance of 
molecular markers, but only few have analyzed the influence 
on invasion and metastasis (12-17). Also, many researchers 
excluded patients with TCs or aggressive forms of thymoma 
with metastatic spread (4,10,16,18,19).
The prediction of the clinical behavior of TETs in biopsies 
or surgical specimens is of clinical relevance, especially for 
planning individualized therapeutic options. The aim of this 
study therefore was to investigate the prognostic value of a 
versatile panel of protein markers in a relatively large number 
of patients with aggressive forms of TET, with special 
attention to invasiveness, metastatic potential and survival. 
Methods
Patients and TET specimens
For this retrospective study, we perused the clinical records 
of all patients who had surgery for WHO type B2/B3 
mixed type thymoma (MT), thymoma type B3 (B3) and 
TC between 1998 and 2013 at our clinic. MTs were only 
included if the tumors contained more than 50% type B3, 
in order to filter aggressive specimens of this group. Tumor 
size was measured as the greatest diameter of the largest 
lesion in a CT or PET/CT scan before surgery, or retrieved 
from the gross pathological report of the resected tumor 
specimen. The study was approved by the institutional review 
board and the local ethics committee (KEK ZH 29-2009). 
Data on gender, age, symptoms, presence of paraneoplastic 
syndromes, preoperative biopsy, tumor size, treatment 
modality, invasion of surrounding organs, completeness 
of resection, metastatic spread and follow-up information 
(recurrence, progression, death) of these patients were 
obtained. 
All cases were pathologically reviewed and subtyped 
according to the revised WHO classification and Masaoka-
Koga staging system by a pathologist experienced in 
intrathoracic tumors (A Soltermann) (5-8). Complete 
resection (R0) was defined as macroscopically and 
microscopically clear surgical margins, incomplete resections 
were classified as either R1 (microscopically positive margins) 
or R2 (grossly residual tumor). Mainly, primary tumor 
specimens were statistically analyzed, tumor specimens of 
recurrent or metastatic disease were, if available, analyzed 
separately. The patients were followed up as long as possible, 
censored on January 20, 2015, and if information was 
missing, the patient or his general practitioner was contacted 
for additional information.
Construction of tissue microarrays (TMAs) and 
immunohistochemical staining
A set of three TMAs with quadruple punches per specimen 
was prepared with a semiautomatic tissue arrayer (Beecher 
Instruments, Sun Prairie, WI, USA) as previously 
described (20). TMA blocks were sectioned and stained with 
H&E (hematoxylin and eosin) for morphologic assessment. 
The used antibodies and detection kits are listed in Table 1. 
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All stainings were performed with automated staining 
instruments (Ventana BenchMark, Ventana, Tucson, AZ, 
USA) and according to vendor’s instructions. Negative and 
positive controls were included in all studies. 
The evaluation of the TMAs was conducted in a blinded 
manner by using an established pathological scoring system 
(H-score): intensity of staining was scored as 0= negative, 
1= weak, 2= moderate or 3= strong, and for each intensity, 
the frequency was indicated in percent (in steps of 10). The 
H-score was then calculated as the sum of: 1× frequency 
of weak staining +2× frequency of moderate staining +3× 
frequency of strong staining. The score per tumor tissue 
sample was calculated as the average of the four punches and 
could range between 0 and 300. No H-score was calculated 
for CD117, podoplanin and synaptophysin; they were 
simply scored as either positive (at least five tumor cells per 
visual field) or negative. Proliferative activity was assessed as 
total proliferation index by counting Ki-67 positive cells in 
three representative visual fields (containing approximately 
100–200 cells each) in percent. p21, p27 and Pax8 were 
evaluated separately for nuclear and cytoplasmic staining, 
whereas for p53, p63, p40 and Ki-67 nuclear staining, for 
Bcl-2, PTEN and synaptophysin cytoplasmic staining, and 
for CD117, CD5 and podoplanin membranous staining 
was considered positive. Low staining of p21 and p27 was 
defined as staining of less than 5% of tumor cell nuclei, 
high staining of p53 as staining of more than 5% of tumor 
cell nuclei as described elsewhere (18,19).
Statistical analysis
Primary endpoint of this study was OS, due to the otherwise 
low number of patients and resulting low statistical power. 
Secondary endpoints were disease-free survival (DFS), 
progression-free survival (PFS), metastasis-free survival 
(MFS), invasion and extrathoracic metastasis. OS was 
defined as the date of diagnosis until death of any cause, 
DFS was calculated from the date after successful treatment 
(date of complete resection or date at the end of adjuvant 
therapy after R0 resection) until clinical or pathological 
evidence of recurrence of the tumor, and PFS was defined 
as the time from the beginning of the treatment until 
progression of the tumor (according to RECIST criteria) 
or death for patients with incomplete resection status. MFS 
was defined as the date of diagnosis until the occurrence 
of radiologically suspected or histologically confirmed 
metastases. Patients with no event were censored at the last 
date of follow-up. 
All data were statistically analyzed using IBM SPSS 
Version 22 for Windows (SPSS Inc., Chicago, IL, USA). 
Impact on survival and on development of metastasis 
was analyzed using the Kaplan-Meier Method with the 
Table 1 Used antibodies and detection kits for immunohistochemical staining
Antibody specificity Clone Company Dilution Detection kit
CD117: polyclonal rabbit anti-human c-kit Polyclonal Dako A/S 1:100 OptiViewKit
CD5: mouse anti-human CD5 4C7 Novocastra 1:20 OptiViewKit
p63: mouse anti-p63 4A4 Ventana Prediluted OptiViewKit
p40: mouse anti-p40 Polyclonal Zytomed Systems 1:50 OptiViewKit
p21 (C-19): rabbit-anti-p21 Polyclonal Santa Cruz Biotechnology, Inc. 1:50 ChromoMapKit
p27: rabbit anti-p27 Polyclonal Santa Cruz Biotechnology, Inc. 1:60 OptiViewKit
p53: mouse anti-human p53 protein DO-7 Dako A/S 1:80 OptiViewKit
Bcl-2: mouse anti-Bcl-2 124 Ventana Prediluted OptiViewKit
Ki-67: rabbit anti-Ki-67 30-9 Ventana Prediluted OptiViewKit
Podoplanin: mouse anti-human podoplanin D2-40 Dako A/S 1:50 OptiViewKit
Synaptophysin: mouse anti-synaptophysin 27G12 Novocastra 1:50 OptiViewKit
PTEN: rabbit anti-PTEN D4.3 Cell Signaling Technology 1:50 UltraViewKit
Pax8: rabbit anti-paired box 8 Polyclonal Protein Tech Group, Inc. 1:400 OptiViewKit
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Log rank test for comparison of the groups, and the Cox 
regression for scale variables. Correlations among clinical 
parameters and staining patterns, as well as among different 
staining patterns themselves were made using the Spearman 
Rank correlation, the Mann-Whitney-U test and cross 
tabulations (with Fisher’s exact test). A P value of less than 
0.05 was considered statistically significant, a P value of less 
than 0.1 defined as trend towards significance or marginal 
significance. 
Results 
Patient characteristics
A total number of 34 patients with MT, B3 and TC were 
included in this study. Due to incomplete clinical data 
or pathological material, or predominantly type B2 MT, 
eleven patients were excluded, thus 23 patients were left for 
statistical analysis. For one patient, only the tumor specimen 
of the recurrent disease (after radiotherapy) could be used 
for pathological evaluation and immunohistochemical 
staining, because the primary surgery was in 1984 and 
pathological material not available anymore. The treatment 
of all other patients was naïve, except for two patients being 
treated either with cortisone and azathioprine or cortisone 
and pyridostigmine. The clinical data is summarized in 
Table 2. The histological subtypes of TC included squamous 
cell carcinoma (n=4), basaloid carcinoma (n=3), and 
neuroendocrine carcinoma (n=2). Paraneoplastic syndromes 
were diagnosed in patients with MT or B3 only. All patients 
except two were treated with surgical excision of the tumor: 
16 patients with resection of the thymus (thymectomy) and 
five with resection of the intrathymic tumor only, meaning 
that part of the thymus was left in the patient. The tumor 
specimens of the remaining two patients were biopsied and 
then treated with palliative chemotherapy in one patient 
and radiotherapy in the other patient. Eleven patients 
received extended surgery: pleurectomy was performed in 
three patients, complete pneumonectomy in two, wedge 
resection of lung tissue in eight and partial resection and 
reconstruction of great vessels in five patients. Selected cases 
additionally received neoadjuvant or adjuvant chemotherapy 
and/or radiotherapy. 
Immunohistochemistry (IHC) of CD117, CD5, p63 and p40
CD117 and CD5 support the diagnosis of TC, therefore 
may predict a worse prognosis, whereas in thymoma they 
are mostly negative (12). p63 has been described as a useful 
marker for thymic epithelial cells and is involved in the 
survival and differentiation of epithelial cells. p40 reacts 
only with three of the six isoforms of p63 (21,22). 
CD117 staining was evaluable in 19 specimens, whereof 
seven were positive, all of which were TCs. CD5 was 
expressed in all tumor specimens (20/20) with a median 
H-score of 168.75 [interquartile range (IQR) 88.125], as well 
as p63 [18/18, median H-score (H) 245, IQR 63.13] and 
p40 (22/22, H 218.75, IQR 76.75). There was no noticeable 
change in expression of these markers in metastatic or relapse 
specimens, except for one case, where the primary tumor was 
weakly positive for p40 (H 67.5) and the relapse completely 
lacked p40 expression (Figure 1A,B).
IHC of tumor suppressors and oncogenes (p21, p27, p53, 
Bcl-2, Ki-67)
These proteins are involved in controlling apoptosis and 
proliferation, and are frequently deregulated in tumor cells. 
Expression of nuclear p21 was generally weak (H 15, IQR 25) 
and completely negative in 4 out of 22 cases, whereas 
cytoplasmic staining was stronger (H 113.75, IQR 48.13) 
and positive in all cases (22/22) (Figure 1C). p27 expression in 
21 specimens was similarly strong in nucleus and cytoplasm 
(H 180, IQR 117.5; H 160, IQR 77.5, respectively), and no case 
was negative. p53 was positive in all cases (22/22) with a median 
H-score of 122.5 (IQR 36.88). The combination of low p21, 
low p27 and high p53 was seen in one patient, whereas p21 low 
and p53 high was present in ten of 22 patients.
Bcl-2 was negative in 12 of 21 cases, nine cases were 
positive with a median H-score of 280 (IQR 76.25). Bcl-2 
expression was observed in eight TC and one MT (Figure 1D). 
Total proliferation index assessed with Ki-67 staining was 
median 20% (IQR 26.25) in 22 patients. 
IHC of podoplanin, synaptophysin, PTEN and Pax8
Podoplanin as a marker for lymphatic endothelium and 
often positive in TETs has been shown to be predictive for 
lymph node metastasis and poor clinical outcome in a variety 
of malignant tumors (16). Pax8, a nuclear transcription 
factor usually only expressed during organogenesis, may be 
reactivated and deregulated in certain tumors. Its influence 
on invasion and metastasis has not been investigated yet (23). 
Furthermore, synaptophysin as a marker for neuroendocrine 
differentiation, and PTEN, a tumor suppressor frequently 
downregulated in tumors, are grouped in this section 
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Table 2 Patient and disease characteristics, and treatment modalities
Characteristics Median/n (%) IQR/n (%) NA
Age at diagnosis 49 years IQR 17 years
Gender Male 14 (60.9) Female 9 (39.1)
Smoking history Yes 10 (43.5) No 13 (56.5)
Range of pack years 3–70
Tumor size at diagnosis 68.5 mm IQR 55.5 mm
Paraneoplastic syndrome Yes 8 (34.8) No 15 (65.2)
Myasthenia gravis 8
Good syndrome 1
Positive ANA, anti ds-DNA, anti Scl-70  antibodies 1
WHO type
B2/B3 4 (17.4)
B3 10 (43.5)
C 9 (39.1)
Masaoka-Koga stage 1
IIA 8 (34.8)
IIB 3 (13.0)
III 5 (21.7)
IVA 3 (13.0)
IVB 3 (13.0)
Preoperative biopsy Yes 8 (34.8) No 14 (60.9) 1
Neoadjuvant chemotherapy Yes 4 (17.4) No 19 (82.6)
ADOC 2
PAC 2
Surgical method 1
Open 12 (52.2)
Minimally invasive 7 (30.4)
Combined 3 (13.0)
Surgical procedure 
Thymectomy 16 (69.6)
Resection of intrathymic tumor 5 (21.7)
Biopsy 2 (8.7)
Residual disease
R0 12 (52.2)
R1 8 (34.8)
R2 (including biopsy) 3 (13.0)
Table 2 (continued)
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Table 2 (continued)
Characteristics Median/n (%) IQR/n (%) NA
Intraoperatively observed macroscopic invasion Yes 14 (60.9) No 7 (30.4) 2 
Lung 8
Pleura 6
Pericardium 8
Vessels 6
Metastatic spread Yes 13 (56.5) No 10 (43.5)
Pleura 8
Lung 8
Lymph nodes 8
Bone 2
Brain 1
Adjuvant therapy Yes 13 (56.5) No 10 (43.5)
Chemotherapy 1
Radiotherapy 12
IQR, interquartile range; NA, not assessable; ADOC, cisplatin doxorubicin vincristine cyclophosphamide; PAC, cisplatin doxorubicin 
cyclophosphamide ; ANA, anti-nuclear antibody; anti ds-DNA, anti-double stranded DNA antibody; anti Scl-70, anti-topoisomerase I antibody.
(24,25). Only one of 20 evaluated cases moderately expressed 
podoplanin (Figure 1E). Synaptophysin was positive in 
7/21 specimens, whereof two were B3 and five were TC 
(basaloid n=2, squamous n=3) (Figure 1F). One of the two 
neuroendocrine carcinomas (NC) included in our study was 
negative for synaptophysin on the TMA and the other was 
not evaluable due to damaged sections; but both specimens 
were positive on the original histological slides. The relapse 
specimen of one of the primarily synaptophysin-positive 
B3 was negative for synaptophysin. H-score of PTEN was 
assessed for 21 patients, which were all positive (H 132.5, 
IQR 46.25). Nuclear and cytoplasmic staining of Pax8 was 
positive in all of 20 evaluated cases, with a median H-score 
of 197.5 (IQR 162.5) and 185 (IQR 75), respectively. The 
results of all immunohistochemical stainings are summarized 
in the supplemental digital content 1 (Table S1).
Survival analysis
Median follow-up was 53.64 months (range, 7–365 months). 
At the time of analysis, 17 patients were alive and six had 
died. One-, 5- and 10-year OS were 91%, 86% and 58%, 
respectively. From the twelve patients with complete 
resection, five patients had recurrent disease. One- and 
5-year DFS were 83% and 69%, respectively. From the 
remaining eleven patients with incomplete resection, five 
patients had progressive disease, and 1- and 5-year PFS 
were 72% and 60%, respectively. The significant results of 
the univariate analysis of the impact of clinical factors and 
staining pattern on OS, DFS and PFS are summarized in 
Table 3. The complete data are shown in Tables S2,S3. Figure 
2A shows the significantly decreased OS if metastases to 
bone occurred. WHO type (C < B3 < B2/B3), subtype of 
TC (neuroendocrine < squamous < basaloid), Masaoka stage 
(III + IV < II and IV < II + III) and metastasis to pleura 
showed a trend towards shorter OS. 
Figure 2B shows a negative impact on DFS by invasion 
into vessels. Synaptophysin positive tumor specimens had a 
trend towards worse DFS. Figure 2C shows the significantly 
shorter PFS for H-score of p21 in cytoplasm. A trend 
towards shorter PFS was seen for tumor size larger than 
the median of the study group (68.5 mm), metastasis and 
metastasis to lung.
Correlations between clinical parameters and 
immunohistochemistry 
Higher age at diagnosis correlated significantly with a 
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Figure 1 Examples of immunohistochemical staining. (A,B) In a case of basaloid TC, the primary tumor showed scattered nuclear expression 
of p40 (dark brown, black arrows mark the outline of one nucleus) whereas the relapse specimen of the same patient was negative for p40; 
(C) p21 was evaluated for nuclear and cytoplasmic staining separately; in this case of a B3, p21 was negative in the nucleus (black arrows), 
but moderately positive in the cytoplasm (white arrow); (D) Bcl-2, an oncogene often positive in TCs, shows strong cytoplasmic expression 
in this case of squamous TC (white arrows mark the cell membrane of a tumor cell); (E) only one case of TC expressed podoplanin (white 
arrow marks the cell membrane), a marker for lymphatic endothelium which can also be positive in thymic epithelial tumor cells; (F) 
neuroendocrine markers are also expressed in non-neuroendocrine TCs, like in this case with weak cytoplasmic expression of synaptophysin 
in a basaloid TC. TC, thymic carcinoma.
10 μm
10 μm
10 μm
10 μm
10 μm
10 μm
A B C
D E F
higher total proliferation index (P=0.013) and H-score of 
Pax8 in cytoplasm (P=0.032), age at diagnosis (P=0.020), 
H-score of CD5 (P=0.005), H-score of p21 in nucleus and 
cytoplasm (P=0.003 and P=0.030, respectively), H-score 
of p27 in nucleus and cytoplasm (P=0.007 and P=0.027, 
respectively), H-score of Bcl-2 (P<0.001), total proliferation 
index (P=0.022) and H-score of Pax8 in cytoplasm (P=0.012) 
were higher in patients with TC compared to MT and B3. 
H-score of PTEN was lower in patients with TC, but not 
statistically significant (P=0.076).
Patients with Masaoka stage III or IV had a higher 
H-score of p21 in cytoplasm than patients with stage II 
(P=0.018) and patients with Masaoka stage IV had larger 
tumors compared to patients with stage II and III (P=0.046). 
H-score of p63 was lower (P=0.097) and H-score of p21 in 
cytoplasm was higher (P=0.096) in patients with Masaoka 
stage IV compared to stage II and III, but not significantly. 
The correlations between the 13 different stainings are 
summarized in Table S4.
Impact on metastatic activity and invasive behavior
Results of the univariate analysis testing the influence of 
clinical factors and staining patterns on the development of 
metastases are shown in Tables S2,S3, significant results are 
summarized in Table 3. Figure 2D shows the significantly 
shorter MFS for tumor size larger than the median. 
A non-significant trend towards shorter MFS was seen 
for patients without paraneoplastic syndrome, subtype of 
TC (neuroendocrine < basaloid < squamous), invasion and 
H-score of p21 in nucleus. 
Extrathoracic metastasis was significantly correlated with 
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Table 3 Survival analysis (significant results)
Characteristics
Significant P value (<0.05)
OS DFS PFS MFS
WHO type (C vs. B3 + B2/B3) 0.021
Masaoka-Koga stage 0.036 <0.001
Masaoka-Koga stage (III + IV vs. II) 0.009 <0.001
Masaoka-Koga stage (IV vs. II + III) 0.023 <0.001
Tumor size over median (68.5 mm) 0.027
Surgical approach (minimally invasive vs. open + combined) 0.031
Surgical procedure (biopsy vs. resection of intrathymic tumor vs. thymectomy) <0.001 0.002 0.026
Invasion into lung (yes vs. no) 0.045
Invasion into pleura (yes vs. no) 0.023 0.001
Invasion into vessels (yes vs. no) 0.047 0.024
Metastasis (yes vs. no) 0.014
Metastasis to pleura (yes vs. no) 0.002
Metastasis to lung (yes vs. no) 0.008
Metastasis to lymph nodes (yes vs. no) 0.034
Metastasis to bone (yes vs. no) <0.001 <0.001
p21 cytoplasm (yes vs. no) 0.016 0.034 0.005
p21 low, p27 low, p53 high (yes vs. no) 0.029
OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; MFS, metastasis-free survival.
R2 resection (P=0.034), higher H-score of p27 in nucleus 
(P=0.042), higher total proliferation index (P=0.024) and 
podoplanin expression (P=0.050). 
Intraoperatively observed macroscopic invasion was 
significantly associated with greater tumor size (P=0.030) 
and marginally significant with higher H-score of p21 in 
cytoplasm (P=0.100). 
Discussion
Immunohistochemical staining pattern and its impact on 
survival, invasive behavior and metastatic potential of TETs 
has gained increased research interest (12). In this study, 
we found that positive staining for p21 in the cytoplasm of 
tumor cells significantly correlated with a decreased OS, 
PFS and MFS. Furthermore, strong positivity for p27 in 
the nucleus, high total proliferation index, and expression 
of podoplanin were significantly related to an increased 
presence of extrathoracic metastases. In contrast, none of 
the tested markers correlated with intraoperatively observed 
macroscopic invasion of surrounding tissue and organs. In 
addition to the immunohistochemical stainings, a particular 
set of clinical factors showed significantly worse survival, 
such as WHO type, Masaoka stage, and metastasis to 
pleura, lung, lymph nodes and bone, some of which have 
been investigated in previous studies with comparable 
results (18,19,26-28) .
Located in the nucleus, p21 and p27 are known to act 
as tumor suppressors and arrest cell cycle progression, and 
they are frequently downregulated in tumor cells (29,30). 
On the other hand, they are exported from the nucleus 
into the cytoplasm through complex mechanisms, where 
they can have a contrary, oncogenic function, e.g., inhibit 
apoptosis or promote invasion (29-31). Most previous 
studies have ignored cytoplasmic staining of p21, p27 
and Pax8 (18,19,23). To the best of our knowledge, this 
is the first study to also investigate cytoplasmic positivity 
of Pax8 in TETs, and cytoplasmic p21 and p27 have been 
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Figure 2 Survival curves. (A) Patients with metastases to bone show significantly worse overall survival (OS) in 23 cases with malignant 
thymic epithelial tumors (TET); (B) disease-free survival (DFS) was significantly worse for patients with intraoperatively observed 
macroscopic invasion into vessels, in 12 cases with completely resected malignant TETs; (C) cytoplasmatically stained p21 (assessed as scale 
variable by H-score) had significant impact on progression-free survival (PFS), shown by this Cox regression survival curve at mean of H-score 
of p21 in cytoplasm of 11 cases with incompletely resected malignant TETs; (D) patients with tumors larger than the median of the study 
group (>68.5 mm) show significantly worse metastasis-free survival (MFS) in 22 analyzed cases with malignant TETs.
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evaluated in only one study so far (32). The relevance of 
cytoplasmic Pax8 staining is still unclear, but it has also 
been described in other neoplasms such as pulmonary 
neuroendocrine tumors (33). In gastric cancer, strong 
cytoplasmic p21 expression significantly correlated with 
lymph node metastasis, distant metastasis, advanced 
TNM stage, depth of invasion and OS (29). In our study, 
cytoplasmic expression of p21 negatively influenced survival 
and significantly correlated with WHO type, Masaoka 
stage and marginally significant with intraoperatively 
observed invasion. As for p27, Omatsu et al. demonstrated 
that cytoplasmic p27 was increased with the increase in 
malignancy of TET (only abstract available) and Chen et al. 
found a significant correlation between cytoplasmic p27 
expression and worse OS and disease-specific survival of 
melanoma patients (30,32). We could confirm a stronger 
cytoplasmic p27 expression in more malignant TETs, but 
no impact on survival was seen. Nuclear export inhibitors, 
such as Selinexor, are currently being tested against 
different cancers in phase I/II human clinical trials and may 
be a promising targeted therapy option also for patients 
suffering from TETs (31).
The combination of low p21, low p27 and high p53 
expression has been shown to significantly decrease DFS 
and predict the response to neoadjuvant chemotherapy 
in patients with thymoma (18,19). In our study, only one 
patient had this combination, but still a significant impact 
on MFS was seen. The influence of combined low p21 and 
high p53 on survival was additionally investigated in our 
study, but no correlation was found. We found remarkably 
strong nuclear expression of p21 and p27 compared to other 
studies. This discrepancy may be explained by the different 
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stainings used: we employed rabbit polyclonal antibodies, 
whereas Mineo et al. used mouse monoclonal antibodies 
(18,19). Moreover, the cytoplasmic overexpression of p21 
and p27 seems to be an important step in the development 
of TETs, rather than their nuclear downregulation. 
Unfortunately, patients with TCs were excluded in both of 
Mineo’s studies. 
Synaptophysin is a commonly used marker to assess 
neuroendocrine differentiation (24). We found seven 
specimens to be positive for synaptophysin, all of which 
were not NC, but had basaloid or squamous differentiation 
or were thymomas type B3. Lauriola et al. have discovered 
early that TCs can express neuroendocrine markers, 
although they morphologically do not look like the 
neuroendocrine tumor type (24). These tumors should be 
graded as carcinomas with neuroendocrine differentiation, 
not as NCs (12). NCs have been shown to have a worse 
prognosis than other subtypes of TCs and are frequently 
excluded in studies (26-28). The two NCs in our study 
exhibited an exceedingly aggressive behavior, they were 
inoperable and could only be biopsied, both were Masaoka 
stage IV, and had a marginally significant lower OS and 
MFS. 
The majority of our patients suffered from invasive 
tumors and metastatic disease which significantly influenced 
survival. There are only few studies that have investigated 
the correlation of immunohistochemical stainings with 
invasion and metastasis, for example: Ki-67 expression 
is associated with MFS and invasiveness (13,14). VEGF 
is more frequently and higher expressed in invasive 
thymomas (14,15). Podoplanin is more often expressed in 
higher stages of thymoma and is positive in metastasized 
tumor cells in lymph nodes. Unfortunately, in this study 
TCs were excluded (16). Additionally, TCs with activated 
STAT3 are more invasive and more often exhibit lymph 
node metastases (17). A comparison with the results of our 
study is difficult due to the divergent patient population 
and different evaluated stainings, but the correlation of 
podoplanin expression and the presence of extrathoracic 
metastases may be an interesting topic for future 
investigations.
Table S4 summarizes the correlation-coefficients and 
corresponding P values of the 13 evaluated stainings. 
Interestingly, many stainings showed a significant 
correlation. However, our study has the following 
undoubtable drawbacks: firstly, the number of patients is too 
limited to allow the performance of an extended statistical 
analysis, including multivariate analysis. Significant results 
in this study may sometimes rely on few patients, thus the 
results should be interpreted critically. Secondly, WHO 
type B2/B3, B3 and TC were analyzed together, which 
may modify outcome. Regarding the first limitation, this 
study, compared to others, still comprises a relatively large 
number of patients with aggressive subtypes of TETs (14-
16,18,19). Fortunately, large international databases have 
recently been created in order to increase the availability 
of data of this rare tumor (26). As for the second downside, 
type B3 thymomas were classified as well-differentiated TC 
before the WHO classification was released, but they are 
still mentioned under this synonyme (5,34). Furthermore, 
Ströbel et al. outlined the close relation of B3 and thymic 
squamous cell carcinoma on the background of partially 
alike genetic abnormalities (35). Therefore, we decided to 
include both B3 and TC in our study. We discovered that 
particular staining patterns and OS significantly varied 
among WHO types; however, DFS, PFS and MFS were 
similar, and many patients with MT and B3 had invasive 
tumors and even developed extrathoracic metastases.
In summary, we found in this  study previously 
undescribed correlations between immunohistochemically 
stainable proteins and survival and metastatic potential of 
aggressive subtypes of TETs. These findings can contribute 
to an improvement of the yet not standardized treatment 
strategy of these rare tumors.
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Table S1 Results of immunohistochemical staining 
Marker Positive N Negative N Median H-score IQR Total N
CD117 7 12 NA NA 19
CD5 20 0 168.75 88.13 20
p63 18 0 245.00 63.13 18
p40 22 0 218.75 76.75 22
p21n 18 4 15.00 25.00 22
p21c 22 0 113.75 48.13 22
p27n 21 0 180.00 117.50 21
p27c 21 0 160.00 77.50 21
p53 22 0 122.50 36.88 22
Bcl-2 9 12 280.00 76.25 21
Ki-67 22 0 20%* 26.25 22
Podoplanin 1 19 NA NA 20
Synaptophysin 7 14 NA NA 21
PTEN 21 0 132.50 46.25 21
Pax8n 20 0 197.50 162.50 20
Pax8c 20 0 185.00 75.00 20
*, indication of median total proliferation index in percent instead of H-score. n, nuclear staining; c, cytoplasmic staining; IQR, interquartile 
range; NA, not assessable. 
Supplementary
Table S2 Survival analysis of clinical parameters
Characteristics
P value
OS DFS PFS MFS
Gender 0.63 0.47 0.712 0.82
Age at diagnosis over median (49 y) 0.87 0.63 0.39 0.38
Smoking 0.87 0.80 0.52 0.94
Paraneoplastic syndrome 0.37 0.19 0.80 0.053
WHO type (C vs. B3 vs. B2/B3) 0.055 0.40 0.28 0.24
WHO type (C vs. B3 + B2/B3) 0.021* 0.29 0.29 0.34
Subtype of WHO type C (neuroendocrine vs. squamous vs. basaloid) 0.051 0.12 0.24 0.089
Masaoka-Koga stage 0.23 0.036* 0.29 <0.001*
Masaoka-Koga stage (III + IV vs. II) 0.076 0.009* 0.30 <0.001*
Masaoka-Koga stage (IV vs. II + III) 0.064 0.023* 0.28 <0.001*
Tumor size over median (68.5 mm) 0.39 0.29 0.091 0.027*
Surgical approach (minimally invasive vs. open + combined) 0.031* 0.52 0.27 0.83
Surgical procedure (biopsy vs. resection of intrathymic tumor vs. thymectomy) <0.001* 0.12 0.002* 0.026*
Invasion 0.67 0.16 0.95 0.066
Invasion into lung 0.98 0.14 0.22 0.045*
Invasion into pleura 0.16 0.023* 0.72 0.001*
Invasion into pericardium 0.50 0.71 0.86 0.87
Invasion into vessels 0.22 0.047* 0.28 0.024*
Residual disease (R2 vs. R1 vs. R0) 0.23 – – 0.86
Metastasis 0.37 0.014* 0.074 –
Metastasis to pleura 0.056 0.45 0.002* –
Metastasis to lung 0.28 0.008* 0.099 –
Metastasis to lymph nodes 0.38 0.034* 0.55 –
Metastasis to bone <0.001* – <0.001* –
Metastasis to brain 0.44 0.23 – –
*, significant P value (P<0.05). OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; MFS, metastasis-free survival. 
Table S3 Survival analysis of immunohistochemical staining 
Marker OS DFS PFS MFS
CD117 P=0.17 P=0.29 P=0.42 P=0.67
CD5 HR 1.016; CI: 0.983–1.050; P=0.35 HR 1.005; CI: 0.985–1.026; P=0.596 HR 1.012; CI: 0.975–1.050; P=0.54 HR 1.002; CI: 0.987–1.016; P=0.83
p63 HR 0.988; CI: 0.961–1.016; P=0.41 HR 0.990; CI: 0.965–1.017; P=0.47 HR 1.006; CI: 0.962–1.051; P=0.81 HR 0.995; CI: 0.975–1.015; P=0.60
p40 HR 0.997; CI: 0.986–1.008; P=0.58 HR 0.992; CI: 0.979–1.005; P=0.23 HR 1.002; CI: 0.988–1.017; P=0.76 HR 0.996; CI: 0.998–1.004;P=0.36
p21 nucleus HR 1.029; CI: 0.990–1.080; P=0.15 HR 1.025; CI: 0.975–1.078; P=0.34 HR 1.127; CI: 0.962–1.319; P=0.14 HR 1.009; CI: 1.000–1.018; P=0.053
p21 cytoplasm HR 1.044; CI: 1.008–1.081; P=0.016* HR 1.041; CI: 0.989–1.096; P=0.12 HR 1.047; CI: 1.004–0.093; P=0.034* HR 1.017; CI: 1.005–1.029; P=0.005*
p27 nucleus HR 1.022; CI: 0.998–1.046; P=0.078 HR 1.013; CI: 0.992–1.035; P=0.23 HR 1.018; CI: 0.996–1.042; P=0.11 HR 1.003; CI: 0.993–1.013; P=0.62
p27 cytoplasm HR 1.014; CI: 0.993–1.036; P=0.20 HR 1.008; CI: 0.985–1.032; P=0.49 HR 1.024; CI: 0.998–1.052; P=0.078 HR 1.003; CI: 0.991–1.015; P=0.59
p53 HR 1.016; CI: 0.998–1.034; P=0.083 HR 1.008; CI: 0.991–1.024; P=0.38 HR 0.999; CI: 0.979–1.019; P=0.92 HR 1.004; CI: 0.993–1.015; P=0.45
p21 low, p27 low, p53 high – – – P=0.029*
p21 low, p53 high P=0.68 P=0.52 P=0.20 P=0.18
Bcl-2 HR 1.007; CI: 0.997–1.018; P=0.18 HR 1.004; CI: 0.996–1.012; P=0.36 HR 1.003; CI: 0.993–1.012; P=0.60 HR 1.001; CI: 0.996–1.006; P=0.64
Ki-67 HR 1.037; CI: 0.976–1.101; P=0.24 HR 1.006; CI: 0.947–1.068; P=0.85 HR 1.081; CI: 0.995–1.174; P=0.064 HR 1.005; CI: 0.967–1.046; P=0.79
Podoplanin P=0.41 P=0.23 – P=0.38
Synaptophysin P=0.24 P=0.10 P=0.85 P=0.91
PTEN HR 0.985; CI: 0.955–1.016; P=0.34 HR 1.004; CI: 0.989–1.020; P=0.60 HR 1.005; CI: 0.963–1.049; P=0.80 HR 1.000; CI: 0.988–1.012; P=0.99
Pax8 nucleus HR 1.0; CI: 0.984–1.016; P=0.98 HR 1.008; CI: 0.992–1.024; P=0.34 HR 1.004; CI: 0.988–1.020; P=0.67 HR 1.002; CI: 0.994–1.010; P=0.58
Pax8 cytoplasm HR 1.008; CI: 0.987–1.030; P=0.45 HR 1.010; CI: 0.992–1.029; P=0.28 HR 0.995; CI: 0.958–1.034; P=0.80 HR 0.999; CI: 0.987–1.012; P=0.90
*, significant P value (P<0.05) and 95% confidence interval. OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; MFS, metastasis-free survival; HR, hazard ratio; CI, 95% confidence interval; P, P value. 
Table S4 Correlations among immunohistochemical stainings (first line: correlation coefficient; second line: correspondent P value)
Correlations CD117 CD5 p63 p40 p21n p21c p27n p27c p53 Bcl-2 Ki67 Podoplanin Synaptophysin PTEN Pax8n Pax8c
CD117 1 Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos
0.005 0.892 0.446 0.090 0.090 0.022 0.047 0.190 <0.001* 0.105 0.368 0.045* 0.069 0.353 0.018*
CD5 Pos 1 0.049 0.058 0.445 0.467 0.534 0.463 0.149 0.583 0.477 Pos Pos −0.384 0.403 0.580
0.005* 0.846 0.807 0.049* 0.038* 0.015* 0.040* 0.530 0.007* 0.033* 0.487 0.104 0.095 0.078 0.007*
p63 Neg 0.049 1 0.816 0.026 0.364 0.514 0.560 0.112 0.138 0.173 Neg Pos 0.577 0.588 0.497
0.892 0.846 <0.001* 0.918 0.137 0.029* 0.016* 0.657 0.584 0.492 0.101 0.389 0.012* 0.010* 0.036*
p40 Neg 0.058 0.816 1 −0.134 0.219 0.352 0.287 0.145 0.208 0.275 Neg Neg 0.465 0.518 0.416
0.446 0.807 <0.001* 0.553 0.328 0.117 0.208 0.520 0.365 0.216 0.099 0.709 0.034* 0.019* 0.068
p21n Pos 0.445 −0.026 −0.134 1 0.538 0.429 0.462 0.272 0.815 0.469 Pos Pos −0.319 0.228 0.333
0.010* 0.049* 0.918 0.553 0.010* 0.052 0.035* 0.220 <0.001* 0.028* 0.253 0.546 0.159 0.334 0.152
p21c Pos 0.467 0.364 0.219 0.538 1 0.543 0.570 0.285 0.518 0.381 Pos Pos 0.056 0.449 0.483
0.090 0.038* 0.137 0.328 0.010* 0.011* 0.007* 0.198 0.016 0.080 0.543 0.116 0.809 0.047* 0.031*
p27n Pos 0.534 0.514 0.352 0.429 0.543 1 0.806 0.155 0.624 0.511 Pos Pos −0.104 0.815 0.887
0.022* 0.015* 0.029* 0.117 0.052 0.011* <0.001 0.503 0.002* 0.018* 0.140 0.136 0.654 <0.001* <0.001*
p27c Pos 0.463 0.560 0.287 0.462 0.570 0.806 1 0.171 0.580 0.426 Pos Pos 0.093 0.590 0.666
0.047* 0.040* 0.016* 0.208 0.035* 0.007* <0.001* 0.458 0.006* 0.054 0.435 0.192 0.690 0.006 0.001
p53 Pos 0.149 0.112 0.145 0.272 0.285 0.155 0.171 1 0.346 −0.008 Pos Pos 0.167 0.289 0.261
0.190 0.530 0.657 0.520 0.220 0.198 0.503 0.458 0.125 0.972 0.340 0.332 0.470 0.217 0.266
Bcl-2 Pos 0.583 0.138 0.208 0.815 0.518 0.624 0.580 0.346 1 0.548 Pos Pos −0.271 0.391 0.605
<0.001* 0.007* 0.584 0.365 <0.001* 0.016 0.002 0.006* 0.125 0.010* 0.377 0.115 0.235 0.088 0.005*
Ki67 Pos 0.477 0.173 0.275 0.469 0.381 0.511 0.426 −0.008 0.548 1 Pos Neg −0.022 0.419 0.552
0.105 0.033* 0.492 0.216 0.028* 0.080 0.018* 0.054 0.972 0.010* 0.113 0.365 0.926 0.066 0.012*
Podoplanin Pos Neg Neg Pos Pos Pos Pos Pos Pos Pos 1 1 Neg Pos Pos
0.368 0.487 0.101 0.099 0.253 0.543 0.140 0.435 0.340 0.377 0.113 0.259 0.260 0.134
Synaptophysin Pos Pos Neg Pos Pos Pos Pos Pos Pos Neg 1 1 Neg Pos Pos
0.045* 0.104 0.389 0.709 0.546 0.116 0.136 0.192 0.332 0.115 0.365 0.654 0.663 0.183
PTEN Neg −0.384 0.577 0.465 −0.319 0.056 −0.104 0.093 0.167 −0.271 −0.022 Neg Neg 1 0.126 −0.029
0.069 0.095 0.012* 0.034* 0.159 0.809 0.654 0.690 0.470 0.235 0.926 0.259 0.654 0.595 0.904
Pax8n Pos 0.403 0.588 0.518 0.228 0.449 0.815 0.590 0.289 0.391 0.419 Pos Pos 0.126 1 0.877
0.353 0.078 0.010* 0.019* 0.334 0.047* <0.001* 0.006* 0.217 0.088 0.066 0.260 0.663 0.595 <0.001
Pax8c Pos 0.580 0.497 0.416 0.333 0.483 0.887 0.666 0.261 0.605 0.552 Pos Pos −0.029 0.877 1
0.018* 0.007* 0.036* 0.068 0.152 0.031* <0.001 0.001 0.266 0.005* 0.012* 0.134 0.183 0.904 <0.001
*, significant P value (<0.05). n, nuclear staining; c, cytoplasmic staining; Pos, positive correlation in the Mann-Whitney-U-test; Neg, negative correlation in the Mann-Whitney-U-test. 
